Pharmacogenetics of asthma.
Pharmacogenetics offers the potential to optimize treatment for individual patients by using genetic information to improve efficacy or avoid side effects. While there are a number of examples in which the approach is already in routine clinical usage, exploitation of this approach in asthma is still under development. A number of examples of possible pharmacogenetic approaches that may prove of value in the management of asthma are discussed.
Hall
Ian P
IP
Division of Therapeutics and Molecular Medicine, University Hospital of Nottingham, Nottingham NG7 2UH, UK. Ian.Hall@nottingham.ac.uk
D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics; D001249:Asthma / Q000188:drug therapy* / Q000235:genetics*; D005838:Genotype; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011943:Receptors, Adrenergic, beta / Q000235:genetics; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000235:genetics; D018077:Receptors, Leukotriene / Q000235:genetics; D012307:Risk Factors; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D011943:Receptors, Adrenergic, beta; D011965:Receptors, Glucocorticoid; D018077:Receptors, Leukotriene; D001094:Arachidonate 5-Lipoxygenase; C083169:leukotriene D4 receptor